Description
Lanluma X 1x40ml – High-Volume PLLA Biostimulator of 630 mg of PLLA
mgLanluma X 1x40ml is a professional injectable poly-L-lactic acid (PLLA) biostimulator suspension designed to address moderate to advanced volume loss, tissue laxity, and age-related structural deficiency across large treatment areas such as the face and body. The product consists of a 40 ml sterile vial of PLLA powder that must be reconstituted prior to administration. Consequently, once injected, Lanluma X stimulates collagen production and dermal renewal, providing gradual and natural-looking volume restoration with extended durability. This product contains 630mg of PLLA built for deep subcutaneous injection in large body areas.
Lanluma X differs from traditional hyaluronic acid fillers, which provide immediate volume through gel implantation. Instead, it promotes neocollagenesis and tissue remodelling, leading to sustained improvements in skin structure and volume over a series of treatments — a critical distinction for practitioners planning long-term aesthetic outcomes.
What Lanluma X Is Similar To
Lanluma X belongs to the family of biostimulatory injectables focused on inducing collagen synthesis. It is clinically comparable to PLLA biostimulators such as Sculptra® in its mechanism of action, which does not rely on gel deposition but on stimulating the body’s own fibroblasts to regenerate collagen. While HA volumisers address fine lines and superficial volume loss, Lanluma X targets deeper structural rejuvenation and volumetric deficiency.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to manufacturer and distributor documentation, Lanluma X 1x40ml with 630mg of PLLA is indicated for:
Treatment areas:
- Body areas with significant volume depletion (e.g., arms, abdomen, buttocks)
-
Structural enhancement in age-related soft tissue descent
→ Lanluma X is ideal for patients with moderate to severe volume loss or those seeking long-lasting collagen stimulation and tissue support beyond what conventional fillers can achieve.
Usage / Administration (IFU-only)
Injection depth: Deep dermal to subcutaneous, depending on anatomy and target volume.
Product preparation: Reconstitution with sterile water for injection according to official protocol; adequate mixing and hydration are essential for optimal distribution.
Injection technique: Administered via cannula or needle in fanned, cross-hatching patterns to cover broad areas of deficit.
Frequency / number of sessions: Treatment typically involves multiple sessions spaced 4–6 weeks apart, with practitioner assessment guiding the number of treatments.
Professional-use disclaimer: Administered only by trained and qualified medical or aesthetic professionals with expertise in collagen biostimulation and large-volume injections.
If any parameter is omitted in the official IFU, it is noted as “not provided by manufacturer.”
Ingredient List (LanlumaX Ingredients)
-
Poly-L-lactic acid (PLLA): 180 mg per vial (40 ml powder)
-
Excipients: Sodium carboxymethylcellulose, mannitol
Lanluma X is supplied as a sterile lyophilised powder and must be reconstituted prior to use. The product does not contain lidocaine.
Presentation & Longevity
Presentation: 1 × 40 ml vial requiring reconstitution.
Shelf-life: Refer to product packaging and IFU for expiry details.
Longevity (treatment duration): Results develop progressively over weeks as collagen synthesis occurs. Clinical outcomes may last 18–24 months or longer, depending on patient variables, injection technique, and treatment plan.
Lanluma X price varies by region, supplier, and clinic pricing strategy; practitioners should consult authorised distributors for current pricing.
Safety Notes / Contraindications
-
Contraindicated in patients with known hypersensitivity to PLLA or any excipient.
-
Avoid use in areas with active infection, inflammation, or compromised tissue.
-
Do not inject intravascularly.
-
Single-use product; do not reuse.
-
Strict aseptic technique and advanced anatomical understanding are required for large-volume biostimulatory injections.
Regulatory Status
Lanluma X is CE-marked as a medical device where applicable. Regulatory classification, approved indications, and usage protocols may vary by jurisdiction; practitioners should verify local compliance via the official IFU or authorised distributor documentation.
FAQ
1. What is Lanluma?
Lanluma refers to a class of poly-L-lactic acid (PLLA) biostimulators designed to stimulate the body’s own collagen production for gradual volumisation and tissue support. Lanluma products differ from traditional fillers because they induce neocollagenesis rather than depositing gel to add immediate volume.
2. How does Lanluma X work in the skin?
Lanluma X is reconstituted and injected into deep dermal or subcutaneous tissue, where the PLLA particles act as a scaffold that promotes fibroblast activation and new collagen formation over time. This leads to progressive improvement in volume, firmness, and skin architecture.
3. Is Lanluma X the same as a dermal filler?
No. While dermal fillers such as HA gels provide immediate volume, Lanluma X works through biostimulation, leading to gradual, long-lasting structural improvements rather than instant physical augmentation.
4. What is the typical treatment protocol and how long do results last?
A typical course involves multiple sessions spaced roughly 4–6 weeks apart. Results emerge gradually over several weeks to months and are often reported to last 18–24 months or longer.
5. What safety considerations should practitioners keep in mind?
Practitioners must use strict aseptic technique, detailed anatomical understanding, careful reconstitution, and appropriate injection patterns. Avoid areas of active infection or compromised tissue and monitor for typical post-treatment responses (e.g., mild swelling, tenderness).
